Funded by a $230,979 grant, an Ohio University study tests metformin to prevent Clostridioides difficile in heart patients.
A critical problem in treating Clostridioides difficile infections is the possibility that the pathogen develops resistance ...
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides ...
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...
Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
High-dose cohort confirms the favorable safety profile and the dose-dependent immune response against Clostridioides difficile bacteria and spores Allschwil, Switzerland - June 1, 2026Idorsia Ltd (SIX ...
STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results